Iron–deficiency anemia during pregnancy and postpartum occurs frequently and may lead to severe maternal complications. The aim of the study was to assess the safety and efficacy of Intravenous ferric carboxymaltose in the management of anemia in pregnant women during the 3^rd trimester.

Methods: Prospective observational study; 60 anemic pregnant women received 1000mg of ferric carboxymaltose between 29 and 34 weeks of pregnancy. Treatment effectiveness was assessed by repeat hemoglobin (Hb) measurement after 2 weeks. Safety was assessed by analysis of adverse drug reactions during the infusion and 2 hours after infusion.

Results: Intravenous ferric carboxymaltose infusion significantly increased hemoglobin values (p < 0.001) above baseline levels in all women. None of the women developed serious adverse events during the study period.

Conclusions: Intra venous ferric carboxymaltose can be used safely in moderate to severe iron deficiency anemia diagnosed later in pregnancy.